TrovaGene Inc(NASDAQ:TROV) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $68.000K. Analysts estimated a revenue of $180.000K. The revenues were -62.22% below the estimates. Earnings per share were $-0.25. The reported EPS was above estimates by 21.88%. Analysts had estimated an EPS of $-0.32.
TrovaGene Inc (TROV) remained unchanged at the close of Friday session. Even as the volume increased to 6,64,440 ,the shares failed to make any impression and ended at 0 points or 0.00% at $1.3. The trading session commenced at $1.3 and the stock hit a high of $1.3 and touched $1.25 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $6.67 and the 52-week low is $1.25. The company has a market cap of $40 M and has approximately 3,09,65,000 outstanding shares.
Several Insider Transactions has been reported to the SEC. On Dec 19, 2016, Stanley Tennant (director) purchased 10,000 shares at $2.10 per share price.Also, On Dec 19, 2016, William J Welch (CEO) purchased 4,750 shares at $2.09 per share price.On Dec 15, 2016, Mark Erlander (Chief Scientific Officer) purchased 5,000 shares at $2.08 per share price, according to the Form-4 filing with the securities and exchange commission.
Trovagene Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Company’s primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology while its external focus includes entering into collaborations to develop its technology in areas such as infectious disease transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).